Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameRainmed-B
Stock Code02297
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家中國醫療器械公司,專注於基於冠狀動脈造影的血流儲備分數系統(caFFR系統)及基於冠狀動脈造影的微血管阻力指數系統(caIMR系統)的設計、開發及商業化,核心產品用於評估冠狀動脈狹窄和微循環功能障礙引起的心肌缺血的嚴重程度。
Listing Date2022-07-08
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)江蘇省蘇州市蘇州工業園區金雞湖大道99號東北區31棟
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.rainmed.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 6.24 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 6,240
Par ValueTo be extracted
Offer Period2022-06-27 to 2022-06-30
Global Offering Shares23,348,000 shares
HK Public Offer Shares (Initial)2,336,000 shares (10.0%)
Public Offer Lots (Initial)2,336lots (Pool A1,168lots,Pool B1,168lots)
International Placing Shares (Initial)21,012,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,167,348,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 145,691,520

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 6,240
2 lots 2,000 HK$ 12,480
3 lots 3,000 HK$ 18,720
4 lots 4,000 HK$ 24,960
5 lots 5,000 HK$ 31,200
6 lots 6,000 HK$ 37,440
7 lots 7,000 HK$ 43,680
8 lots 8,000 HK$ 49,920
9 lots 9,000 HK$ 56,160
10 lots 10,000 HK$ 62,400
15 lots 15,000 HK$ 93,600
20 lots 20,000 HK$ 124,800
25 lots 25,000 HK$ 156,000
30 lots 30,000 HK$ 187,200
35 lots 35,000 HK$ 218,400
40 lots 40,000 HK$ 249,600
50 lots 50,000 HK$ 312,000
60 lots 60,000 HK$ 374,400
70 lots 70,000 HK$ 436,800
80 lots 80,000 HK$ 499,200
90 lots 90,000 HK$ 561,600
100 lots 100,000 HK$ 624,000
150 lots 150,000 HK$ 936,000
200 lots 200,000 HK$ 1,248,000
400 lots 400,000 HK$ 2,496,000
800 lots 800,000 HK$ 4,992,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
900 lots 900,000 HK$ 5,616,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 299.8M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +3140%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,284,251,520
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣633.6百萬元
Period-End Cash Balance人民幣559.1百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20202021
Profit for the year -145,240-633,646
Balance Sheet
Item 20202021
Cash and cash equivalents 27,588559,140
Inventories 5,3139,908
Total current assets 38,371575,645
Total assets 70,522640,192
Total current liabilities 52,98544,067
Total liabilities 291,4631,414,676
Total equity -220,941-774,484
Equity attributable to owners -220,933-774,484
Interest-bearing borrowings 11,0200
Cash Flow Statement
Item 20202021
Net cash from operating activities 2,271-72,832
Net cash from investing activities 8,685-27,983
Net cash from financing activities 9,526633,847
Net increase in cash 20,482533,032
Purchase of PP&E -3,998-30,835
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 5.28
First Day OpenHK$ 5.6
First Day Change-15.38%
First Day Volume5633000.0
First Day Turnover32209800.0
Use of Proceeds
1、80.0%或約63.1百萬港元將撥作我們的核心產品caFFR系統及caIMR系統; 2、16.5%或約13.2百萬港元將撥作其他管線產品的持續研發、生產及商業化的資金; 3、3.5%或約2.7百萬港元將撥作一般營運資金及一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (4)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 交银国际证券有限公司 CE APJ121 Eddid Securities and Futures Limited CE BHT550
Joint Lead Managers (5)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 交银国际证券有限公司 CE APJ121 Eddid Securities and Futures Limited CE BHT550 Livermore Holdings Limited CE BJN764

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman霍雲飛—
Company Secretary張亮、朱卓婷—
No director data available.

Major Shareholders

Major Shareholders & Holdings霍雲飛先生透過Opera Rose Limited等持有約18.66%,霍雲龍博士透過Vermilion Bird Limited持有約13.70%,平安集團持有約10.28%,同襄灝乾及同創偉業集團合共持有約11.10%,周彬先生持有約7.09%,河北東拓投資有限公司持有約5.12%,上海景邁潤持有約5.05%。
About this page

This page shows Rainmed-B (02297) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect